Dbv Technologies SA

NASDAQ:DBVTUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Contact Information

Headquarters

Batiment IRO, 107 Av. de la RepubliqueCHATILLON, France 92320

Phone

---

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Michel De Rosen

Chief Executive Officer, Director

Daniel Tasse

Chief Financial Officer

Virginie Boucinha

Chief Medical Officer

Pharis Mohideen

Chief Regulatory Officer

Robert Pietrusko